An artificial intelligence firm announced that it will end its partnership with Chinese companies following the United States issuing security concerns.
Pfizer announced last week that it is discontinuing development of its twice-daily weight loss pill "danuglipron" after a clinical trial showed "high rates" of adverse side effects among users.